MedInCell Stock Tests Key Technical Support Despite +77% Yearly Gain
The Montpellier-based biotech stock fell this Monday, April 13, amid a general pullback in European markets. MedInCell traded at 22.80 euros during the session, down 1.81% from last Friday's close. The company, which will publish its annual results on June 16, shows a contrast between a strong annual performance and a less favorable recent quarter.
Current Session Overview
During the session, MedInCell fell by 1.81% to 22.80 euros, following the CAC 40, which lost 1.01% at 8,176.58 points. The SBF 120 also dropped by 1.01%. Other healthcare sector stocks followed the same trajectory, like Sanofi (-1.46%) and UCB (-0.87%). Over the past week, the stock has declined by 1.3%, while over three months, the correction reached 13.7%. This movement contrasts with the year-on-year performance, which remains strongly positive at +77.57%. The next key event for the company will be the publication of its annual results for the fiscal year 2025-2026, scheduled for June 16, followed by the general meeting on September 10.
Technical Analysis
From a technical standpoint, MedInCell's share price is currently very close to its 50-day moving average, set at 22.78 euros, which now acts as a pivotal zone. However, the 200-day moving average is at 23.64 euros, above the current price, indicating a slight weakening of the medium-term momentum compared to the long-term trend. The Relative Strength Index (RSI), which measures overbought or oversold conditions of a stock, stands at 57, indicating a neutral zone without extreme signals. As for the Bollinger Bands, the price is positioned in the upper part of the band (77%), between an upper limit at 23.70 euros and a lower limit at 19.74 euros. The nearest resistance threshold is at 24.04 euros, a level that needs to be crossed to trigger an upward acceleration. The major support to watch remains set at 20.24 euros.
